CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 6, 2010, Pages 693-698

  Carbonell, N ^a   Verstuyft, C ^b   Massard, J ^c   Letierce, A ^d   Cellier, C ^e   Deforges, L ^f   Saliba, F ^b   Delchier, J C ^f   Becquemont, L ^b,d  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIULCER AGENT; CELECOXIB; CLOPIDOGREL; CYTOCHROME P450 2C9; DICLOFENAC; FLURBIPROFEN; GLUCOCORTICOID; IBUPROFEN; KETOPROFEN; LEUCINE; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; TENOXICAM; TICLOPIDINE; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; CASE STUDY; DRUG METABOLISM; DRUG USE; FEMALE; GENOTYPE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GASTROINTESTINAL HEMORRHAGE; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77952582733     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.33     Document Type: Article

References (28)

1. Gralnek, I.M., Barkun, A.N. & Bardou, M. Management of acute bleeding from a peptic ulcer. N. Engl. J. Med. 359, 928-937 (2008).
2. Wolfe, M.M., Lichtenstein, D.R. & Singh, G. Gastrointestinal toxicity of nonsteroidal antiinfammatory drugs. N. Engl. J. Med. 340, 1888-1899 (1999).
3. Hermansson, M., Ekedahl, A., Ranstam, j. & Zilling, T. Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. BMC Gastroenterol. 9, 25 (2009).
4. Graham, D.Y. NSAIDs, Helicobacter pylori, and Pandora's Box. N. Engl. J. Med. 347, 2162-2164 (2002).
5. Bhatt, D.L. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52, 1502-1517 (2008).
6. Kirchheiner, j. & Brockmöller, j. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16 (2005).
7. Rodrigues, A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos. 33, 1567-1575 (2005).
8. Hutt, A.J., Caldwell, J. & Smith, R.L. The metabolism of aspirin in man: a population study. Xenobiotica 16, 239-249 (1986).
9. Blanco, G. et al. Interaction of CYP2C8 and CYP2C9 genotypes modifes the risk for nonsteroidal anti-infammatory drugs-related acute gastrointestinal bleeding. Pharmacogenet. Genomics 18, 37-43 (2008).
10. Martínez, C. et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol. 141, 205-208 (2004).
11. Pilotto, A. et al. Genetic susceptibility to nonsteroidal anti-infammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 133, 465-471 (2007).
12. Vonkeman, H.E., van de Laar, M.A., van der Palen, j., Brouwers, j.R. & Vermes, I. Allele variants of the cytochrome P450 2C9 genotype in white subjects from The Netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs. Clin. Ther. 28, 1670-1676 (2006).
13. Martin, J.H., Begg, E.J., Kennedy, M.A., Roberts, R. & Barclay, M.L. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br. J. Clin. Pharmacol. 51, 627-630 (2001).
14. Ma, J., Yang, X.Y., Qiao, L., Liang, L.Q. & Chen, M.H. CYP2C9 polymorphism in non-steroidal anti-infammatory drugs-induced gastropathy. J. Dig. Dis. 9, 79-83 (2008).
15. Yang, J.Q. et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol. 17, 373-376 (2003).
16. Yamazaki, H. et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys-and Leu-variants in the oxidation of warfarin, furbiprofen, and diclofenac by human liver microsomes. Biochem. Pharmacol. 56, 243-251 (1998).
17. Kirchheiner, J., Störmer, E., Meisel, C., Steinbach, N., Roots, I. & Brockmöller, j. Infuence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 13, 473-480 (2003).
18. Kirchheiner, J., Meineke, I., Freytag, G., Meisel, C., Roots, I. & Brockmöller, j. Enantiospecifc efects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin. Pharmacol. Ther. 72, 62-75 (2002).
19. Lee, C.R., Pieper, J.A., Frye, R.F., Hinderliter, A.L., Blaisdell, J.A. & Goldstein, j.A. Diferences in furbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur. J. Clin. Pharmacol. 58, 791-794 (2003).
20. Vianna-Jorge, R., Perini, J.A., Rondinelli, E. & Suarez-Kurtz, G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 76, 18-26 (2004).
21. Totah, R. & Rettie, A. Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmaco. Ther. 77 (2005).
22. Dai, D. et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597-607 (2001).
23. Rodríguez-Antona, C. et al. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 8, 268-277 (2008).
24. Aquilante, C.L., Bushman, L.R., Knutsen, S.D., Burt, L.E., Rome, L.C., Kosmiski, L.A. Infuence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum. Genomics 3, 7-16 (2008).
25. López-Rodríguez, R. et al. Infuence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. Pharmacol. Res. 58, 77-84 (2008).
26. Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B. & Brockmöller, j. Efect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 44, 1209-1225 (2005).
27. Morin, S. et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. 75, 403-414 (2004).
28. Verstuyft, C. et al. A new, rapid and robust genotyping method for CYP2C9 and MDR1. Ann. Biol. Clin. (Paris) 61, 305-309 (2003).